Literature DB >> 24088143

Introduction: Institutional corruption and the pharmaceutical policy.

Marc A Rodwin1.   

Abstract

Today, the goals of pharmaceutical policy and medical practice are often undermined due to institutional corruption - that is, widespread or systemic practices, usually legal, that undermine an institution's objectives or integrity. In this symposium, 16 articles investigate the corruption of pharmaceutical policy, each taking a different look at the sources of corruption, how it occurs, and what is corrupted. We will see that the pharmaceutical industry's own purposes are often undermined. Furthermore, pharmaceutical industry funding of election campaigns and lobbying skews the legislative process that sets pharmaceutical policy. Moreover, certain practices have corrupted medical research, the production of medical knowledge, the practice of medicine, drug safety, the Food and Drug Administration's oversight of the pharmaceutical market, and the trustworthiness of patient advocacy organizations.
© 2013 American Society of Law, Medicine & Ethics, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 24088143     DOI: 10.1111/jlme.12062

Source DB:  PubMed          Journal:  J Law Med Ethics        ISSN: 1073-1105            Impact factor:   1.718


  8 in total

1.  Relationships between physicians and Pharma: Why physicians should not accept money from the pharmaceutical industry.

Authors:  Carl Elliott
Journal:  Neurol Clin Pract       Date:  2014-04

2.  Quaternary prevention, an answer of family doctors to overmedicalization.

Authors:  Marc Jamoulle
Journal:  Int J Health Policy Manag       Date:  2015-02-04

3.  Ophthalmology Patient Perceptions of Open Payments Information.

Authors:  Gregory E Stein; Jonathan J Kamler; Jonathan S Chang
Journal:  JAMA Ophthalmol       Date:  2018-12-01       Impact factor: 7.389

4.  Steps to strengthen ethics in organizations: research findings, ethics placebos, and what works.

Authors:  Kenneth S Pope
Journal:  J Trauma Dissociation       Date:  2015-01-20

5.  Hospital physician payment mechanisms in Austria: do they provide gateways to institutional corruption?

Authors:  Margit Sommersguter-Reichmann; Adolf Stepan
Journal:  Health Econ Rev       Date:  2017-03-01

6.  Moving towards a better path? A mixed-method examination of China's reforms to remedy medical corruption from pharmaceutical firms.

Authors:  Jianwei Shi; Rui Liu; Hua Jiang; Chunxu Wang; Yue Xiao; Nana Liu; Zhaoxin Wang; Leiyu Shi
Journal:  BMJ Open       Date:  2018-02-08       Impact factor: 2.692

Review 7.  Individual and Institutional Corruption in European and US Healthcare: Overview and Link of Various Corruption Typologies.

Authors:  Margit Sommersguter-Reichmann; Claudia Wild; Adolf Stepan; Gerhard Reichmann; Andrea Fried
Journal:  Appl Health Econ Health Policy       Date:  2018-06       Impact factor: 2.561

8.  Plastic Surgeons' Perceptions of Financial Conflicts of Interest and the Sunshine Act.

Authors:  Taylor E Purvis; Joseph Lopez; Jacqueline Milton; James W May; Amir H Dorafshar
Journal:  Plast Reconstr Surg Glob Open       Date:  2018-04-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.